External pharmaceutical preparation for preventing and treating rheumatoid arthritis

A pharmaceutical preparation and rheumatoid technology, applied in the field of medicine, can solve the problems of limited dosage, increased frequency of administration, unfavorable drug effect, etc., and achieve the effect of enhanced synergistic effect

Inactive Publication Date: 2018-09-18
邛崃市医疗中心医院
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the topical preparation can reduce the incidence of adverse reactions to a certain extent compared with oral preparations, and can specifically target local lesions, its single dose is limited and the drug release time is short, which will lead to an

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • External pharmaceutical preparation for preventing and treating rheumatoid arthritis
  • External pharmaceutical preparation for preventing and treating rheumatoid arthritis
  • External pharmaceutical preparation for preventing and treating rheumatoid arthritis

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0018] Example 1

[0019] Take commercially available medicinal NAB, Ligusticum chuanxiong oil, azone, medicinal excipients hydroxypropyl methylcellulose, ethanol, propylene glycol, ethyl p-hydroxybenzoate and purified water, etc., and prepare according to the existing preparation method of gel A gel containing 1.0% (mass, the same below) NAB, 1.0% (mass) Ligusticum chuanxiong oil and 1.0% (mass) azone (mass ratio of azone and Ligusticum chuanxiong oil 1:1), namely sample 1. In the gel, hydroxypropyl methylcellulose is used as an excipient, and its content is 1.0%.

Example Embodiment

[0020] Example 2

[0021] Take commercially available medicinal NAB, Ligusticum chuanxiong oil, azone, medicinal excipients hydroxypropyl methylcellulose, ethanol, propylene glycol, ethyl p-hydroxybenzoate and purified water, etc., and prepare according to the existing preparation method of gel A gel containing 0.7% NAB, 3.0% Ligusticum chuanxiong oil and 1.0% Azone (mass ratio of azone and Ligusticum chuanxiong oil 1:3), namely sample 2. The content of hydroxypropyl methylcellulose in the gel is 1.0%.

Example Embodiment

[0022] Example 3

[0023] Take commercially available medicinal NAB, Ligusticum chuanxiong oil, azone, medicinal excipients hydroxypropyl methylcellulose, ethanol, propylene glycol, ethyl p-hydroxybenzoate and purified water, etc., and prepare according to the existing preparation method of gel A gel containing 0.5% NAB, 1.0% Ligusticum chuanxiong oil and 2.0% Azone (mass ratio of azone and Ligusticum chuanxiong oil 2:1), namely sample 3. The content of hydroxypropyl methylcellulose in the gel is 1.0%.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an external pharmaceutical preparation for preventing and treating rheumatoid arthritis. The external pharmaceutical preparation contains nabumetone, a mixture of azone and rhizoma chuanxiong oil, hydroxypropyl methyl cellulose and pharmaceutically acceptable other auxiliary additive components, wherein nabumetone is taken as an effective pharmaceutical component, the mixture of azone and rhizoma chuanxiong oil is taken as a transdermal agent, the hydroxypropyl methyl cellulose is taken as a matrix, the mass content of the transdermal agent is 0.5%-10%, and the mass ratio of azone to rhizoma chuanxiong oil is (0.01-5) to 1. According to the external pharmaceutical preparation, the hydroxypropyl methyl cellulose is taken as the matrix, rhizoma chuanxiong oil and azone can generate a synergistic interaction effect on promoting nabumetone to penetrate through skin when being commonly taken as the transdermal agent, and particularly, the synergistic interaction effect is remarkably improved when rhizoma chuanxiong oil and azone are in the proportion range of the invention.

Description

technical field [0001] The invention relates to the field of medicine, more specifically, the invention relates to an external pharmaceutical preparation for preventing and treating rheumatoid arthritis. Background technique [0002] Rheumatoid arthritis (Rheumatoid Arthritis, RA, the same below) is an autoimmune disease mainly manifested by chronic inflammatory lesions of synovial joints, and the incidence rate in my country is about 0.32%-0.36%. Drug therapy for RA patients mainly includes two aspects: analgesia and disease-modifying treatment. Analgesics, non-steroidal anti-inflammatory drugs (NSAIDs, the same below), and glucocorticoids mainly achieve the purpose of relieving joint pain in patients. The benefits of this treatment are short-term and can only be used as adjuvant therapy, which makes RA patients The main treatment for long-term benefits is to use disease-modifying drugs. NSAIDs mainly inhibit the activity of cyclooxygenase (Cyclooxygenase, COX, the same be...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K47/46A61K47/22A61K47/38A61K31/12A61P19/02A61P29/00
CPCA61K9/0014A61K31/12A61K47/22A61K47/38A61K47/46A61P19/02A61P29/00
Inventor 邱建平谭正怀曾明辉熊静悦陈荟旭刘红
Owner 邛崃市医疗中心医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products